Literature DB >> 33186063

Gradient of Risk and Associations With Cardiovascular Efficacy of Ertugliflozin by Measures of Kidney Function: Observations From VERTIS CV.

David Z I Cherney1, Darren K McGuire2, Bernard Charbonnel3, Francesco Cosentino4, Richard Pratley5, Samuel Dagogo-Jack6, Robert Frederich7, Mario Maldonado8, Jie Liu9, Annpey Pong10, Chih-Chin Liu10, Christopher P Cannon11.   

Abstract

Entities:  

Keywords:  cardiovascular disease; diabetes mellitus, type 2; diabetic nephropathies; heart failure; kidney diseases; renal insufficiency, chronic

Mesh：

Substances：

Year:  2020        PMID： 33186063     DOI： 10.1161/CIRCULATIONAHA.120.051901

Source DB:  PubMed          Journal:  Circulation        ISSN： 0009-7322            Impact factor:   29.690


× No keyword cloud information.
  8 in total

Review 1.  Prevention of Cardiorenal Complications with Sodium-Glucose Cotransporter Type 2 Inhibitors: A Narrative Review.

Authors:  Manuel Botana; Javier Escalada; Ángel Merchante; Rebeca Reyes; Pedro Rozas
Journal:  Diabetes Ther       Date:  2022-06-15       Impact factor: 3.595

Review 2.  Prescribing SGLT2 Inhibitors in Patients With CKD: Expanding Indications and Practical Considerations.

Authors:  Kevin Yau; Atit Dharia; Ibrahim Alrowiyti; David Z I Cherney
Journal:  Kidney Int Rep       Date:  2022-05-05

3.  Effect of dapagliflozin on kidney and cardiovascular outcomes by baseline KDIGO risk categories: a post hoc analysis of the DAPA-CKD trial.

Authors:  Simke W Waijer; Priya Vart; David Z I Cherney; Glenn M Chertow; Niels Jongs; Anna Maria Langkilde; Johannes F E Mann; Ofri Mosenzon; John J V McMurray; Peter Rossing; Ricardo Correa-Rotter; Bergur V Stefansson; Robert D Toto; David C Wheeler; Hiddo J L Heerspink
Journal:  Diabetologia       Date:  2022-04-21       Impact factor: 10.460

Review 4.  Cardiorenal Protection in Diabetic Kidney Disease.

Authors:  Jason F Lee; Ecaterina Berzan; Vikas S Sridhar; Ayodele Odutayo; David Z I Cherney
Journal:  Endocrinol Metab (Seoul)       Date:  2021-04-19

5.  Network Meta-Analysis on the Effects of SGLT2 Inhibitors Versus Finerenone on Cardiorenal Outcomes in Patients With Type 2 Diabetes and Chronic Kidney Disease.

Authors:  Li-Min Zhao; Ze-Lin Zhan; Jie Ning; Mei Qiu
Journal:  Front Pharmacol       Date:  2022-01-24       Impact factor: 5.810

6.  Heart and Kidney Outcomes With Ertugliflozin in People with Non-albuminuric Diabetic Kidney Disease: A post hoc Analysis from the Randomized VERTIS CV Trial.

Authors:  David Z I Cherney; Samuel Dagogo-Jack; Francesco Cosentino; Richard E Pratley; Robert Frederich; Mario Maldonado; Chih-Chin Liu; Christopher P Cannon
Journal:  Kidney Int Rep       Date:  2022-05-13

7.  Optimising the Heart Failure Treatment Pathway: The Role of SGLT2 Inhibitors.

Authors:  Marc Evans; Angharad R Morgan; Zaheer Yousef; Gethin Ellis; Umesh Dashora; Dipesh C Patel; Pam Brown; Wasim Hanif; Johnathan N Townend; Naresh Kanumilli; Jim Moore; John P H Wilding; Stephen C Bain
Journal:  Drugs       Date:  2021-06-23       Impact factor: 9.546

8.  Optimizing sodium-glucose co-transporter 2 inhibitor use in patients with heart failure with reduced ejection fraction: A collaborative clinical practice statement.

Authors:  Bruce A Warden; Johannes Steiner; Albert Camacho; Khoa Nguyen; Jonathan Q Purnell; P Barton Duell; Courtney Craigan; Diane Osborn; Sergio Fazio
Journal:  Am J Prev Cardiol       Date:  2021-04-15
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.